AnodyneWiki

Scopolamine

Scopolamine
Scopolamine
Salts
[]
Scopolamine hemisulfate
Scopolamine hemisulfate
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass303.35 g/mol [1]
Melting point59 °C [1]
Solubility1.0X10+5 mg/L [1]
Predicted LogP0.9 [1]
Structural Identifiers
[]
Molecular formulaC17H21NO4
IUPAC name[(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate
SMILESCN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4
InChIInChI=1S/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11?,12-,13-,14+,15-,16+/m1/s1
InChIKeySTECJAGHUSJQJN-USLFZFAMSA-N
CAS number51-34-3
UNIIDL48G20X8X
PubChem CID3000322
Pharmacokinetics[]
Elimination half-life5 hours
MetabolismLiver (CYP3A4)[3]
ExcretionKidney
Routes of administrationBy mouth, transdermal, ophthalmic, subcutaneous, intravenous, sublingual, rectal, buccal, transmucosal, intramuscular

Scopolamine (also known as Scopace, Hyoscine, (-)-Hyoscine, Scopine tropate, Transderm-Scop, (-)-Scopolamine, Scopine (-)-tropate, Atrochin, Hyosol or l-Scopolamine) is a substance of the tropane class.

Chemistry

Salts []

Scopolamine is typically found in the form of its hemisulfate salt.

 []

Scopolamine is a single defined stereoisomer.

Scopolamine matches Lipinski's rule of five.

There are currently 4 reagent-interactions on

ReagentColor changeDescription
Marquisyellow
Meckeyellow
Mandelinlight green
Ehrlichno color change

Pharmacology

Mechanism of action []

[Acetylcholine] (ACh) is a neurotransmitter that can signal through ligand-gated cation channels (nicotinic receptors) and G-protein-coupled muscarinic receptors (mAChRs). ACh signalling via mAChRs located in the central nervous system (CNS) and periphery can regulate smooth muscle contraction, glandular secretions, heart rate, and various neurological phenomena such as learning and memory. mAChRs can be divided into five subtypes, M1-M5, expressed at various levels throughout the brain. Also, M2 receptors are found in the heart and M3 receptors in smooth muscles, mediating effects apart from the direct modulation of the parasympathetic nervous system. While M1, M3, and M5 mAChRs primarily couple to G<sub>q</sub> proteins to activate phospholipase C, M2 and M4 mainly couple to G<sub>i/o</sub> proteins to inhibit adenylyl cyclase and modulate cellular ion flow. This system, in part, helps to control physiological responses such as nausea and vomiting. Scopolamine acts as a non-selective competitive inhibitor of M1-M5 mAChRs, albeit with weaker M5 inhibition; as such, scopolamine is an anticholinergic with various dose-dependent therapeutic and adverse effects. The exact mechanism(s) of action of scopolamine remains poorly understood. Recent evidence suggests that M1 (and possibly M2) mAChR antagonism at interneurons acts through inhibition of downstream neurotransmitter release and subsequent pyramidal neuron activation to mediate neurological responses associated with stress and depression. Similar antagonism of M4 and M5 receptors is associated with potential therapeutic benefits in neurological conditions such as schizophrenia and substance abuse disorders. The significance of these observations to scopolamine's current therapeutic indications of preventing nausea and vomiting is unclear but is linked to its anticholinergic effect and ability to alter signalling through the CNS associated with vomiting. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

shared target30
shared target24
shared target22
shared target20
shared target20

Medical side effects []

78 side effects listed on drug labels in (scopolamine).

  • Abdominal pain
  • Amblyopia
  • Amnesia
  • Mental disorder
  • Confusional state
  • Feeling abnormal
  • Dizziness
  • Dysuria
  • Strangury
  • Eye disorder
  • Angle closure glaucoma
  • Hallucination
  • Headache
  • Hypotension
  • Nausea
  • Nervous system disorder
  • Pruritus
  • Speech disorder
  • Hyperhidrosis
  • Erythema
  • Redness
  • Urethral disorder
  • Urinary tract disorder
  • Vertigo
  • Vomiting
  • Agitation
  • Excitement
  • Muscular weakness
  • Skin irritation
  • Skin disorder
  • Disorientation
  • Disturbance in attention
  • Acute psychosis
  • Dry eye
  • Bradycardia
  • Rash generalised
  • Application site pain
  • Application site burn
  • Eyelid irritation
  • Psychotic disorder
  • Paranoia
  • Arrhythmia
  • Constipation
  • Dysphagia
  • Dental caries
  • Somnolence
  • Eczema
  • Oedema
  • Dermatitis
  • Rash
  • Asthenia
  • Fatigue
  • Body temperature increased
  • Flushing
  • Heat exhaustion
  • Heat stroke
  • Irritability
  • Mydriasis
  • Pain
  • Pharyngitis
  • Tachycardia
  • Thirst
  • Tremor
  • Dry mouth
  • Urinary retention
  • Photophobia
  • Depressed level of consciousness
  • Dry skin
  • Drug withdrawal syndrome
  • Conjunctivitis
  • Temperature intolerance
  • Hallucination, visual
  • Accommodation disorder
  • Cycloplegia
  • Vision blurred
  • Procedural nausea
  • Poisoning
  • Visual impairment

Indications

  • Amnesia
  • Cycloplegia
  • Delirium tremens
  • Iridocyclitis
  • Motion sickness
  • Mydriasis
  • Nausea
  • Salivation
  • Vomiting

Experience reports

Erowid

There are currently 22 experience reports involving scopolamine on : []

Reddit

There are currently 2 trip reports involving scopolamine on : []

 []

  • Australia: Scopolamine is a S4 / S2.[4]
  • United Kingdom: Scopolamine is Prescription only / P.[5][6]
  • United States: Scopolamine is Prescription only.[7]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 3000322, Scopolamine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3000322
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Scopolamine. UNII: DL48G20X8X. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/DL48G20X8X
  3. Renner UD, Oertel R, Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Therapeutic Drug Monitoring. October 2005; 27(5):655–665. PMID 16175141. https://doi.org/10.1097/01.ftd.0000168293.48226.57
  4. Poisons Standard October 2020. Federal Register of Legislation. 30 September 2020. https://www.legislation.gov.au/Details/F2020L01255
  5. Hyoscine 400 micrograms/ml Solution for Injection. (emc). 18 September 2017. https://www.medicines.org.uk/emc/product/3581/smpc
  6. Kwells 300 microgram tablets Summary of Product Characteristics (SmPC). (emc). 2 September 2020. https://www.medicines.org.uk/emc/product/11746/smpc
  7. Transderm Scop - scopolamine patch, extended-release. DailyMed. 14 March 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b877a694-a1d0-4280-937a-a06820b12a88

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 12:52:30
drugsprook2026-11-20 12:52:26
erowidok2026-11-20 12:52:28
gsrsok2026-11-20 12:52:27
hmdbmissing (no HMDB id)2026-11-20 12:52:26
keggok2026-11-20 12:52:29
pubchemok2026-11-20 12:52:25
redditok2026-11-20 12:52:26
siderok2026-11-20 12:52:26
structureok2026-11-20 12:52:26
wikipediaok2026-11-20 12:52:26